Therapeutic lymph node dissection in melanoma: Different prognosis for different macrometastasis sites?

Annals of Surgical Oncology

Volumn 19, Issue 12, 2012, Pages 3913-3918

  Wevers, K P ^a   Bastiaannet, E ^a   Poos, H P A M ^a   Van Ginkel, R J ^a   Plukker, J T ^a   Hoekstra, H J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; CANCER GROWTH; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CERVICAL LYMPH NODE; CONTROLLED STUDY; CYTOPATHOLOGY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INGUINAL LYMPH NODE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; PECTORAL MUSCLE; PREDICTIVE VALUE; RECURRENT CANCER; SENTINEL LYMPH NODE; THERAPEUTIC LYMPH NODE DISSECTION; WHOLE BODY PET;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AXILLA; FEMALE; FOLLOW-UP STUDIES; GROIN; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84868111181     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2401-8     Document Type: Article

References (22)

1. Dutch Comprehensive Cancer Centers. 2011. http://ikcnet.nl/. Accessed August 2011.
2. van der Aa MA, de Vries E, Hoekstra HJ, Coebergh JW, Siesling S. Sociodemographic factors and incidence of melanoma in the Netherlands, 1994-2005. Eur J Cancer. 2011;47:1056-60.
3. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-206.
4. Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol. 2005;6:608-21. (Pubitemid 41051939)
5. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28: 2452-9.
6. Balch CM, Soong SJ, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224:255-63.
7. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet. 1998;351(9105):793-6. (Pubitemid 28112341)
8. Hughes TM, A'Hern RP, Thomas JM. Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma. Br J Surg. 2000;87:892-901. (Pubitemid 30487692)
9. van Akkooi AC, Bouwhuis MG, van Geel AN, Hoedemaker R, Verhoef C, Grunhagen DJ, et al. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. Eur J Surg Oncol. 2007;33:102-8. (Pubitemid 46131880)
10. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on cancer melanoma staging system. J Clin Oncol. 2001;19: 3622-34. (Pubitemid 32786275)
11. Kruijff S, Bastiaannet E, Kobold AC, van Ginkel RJ, Suurmeijer AJ, Hoekstra HJ. S-100B concentrations predict disease-free survival in stage III melanoma patients. Ann Surg Oncol. 2009; 16:3455-62.
12. Murali R, Desilva C, Thompson JF, Scolyer RA. Factors predicting recurrence and survival in sentinel lymph node-positive melanoma patients. Ann Surg. 2011;253:1155-64.
13. Lachiewicz AM, Berwick M, Wiggins CL, Thomas NE. Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the surveillance, epidemiology, and end results (SEER) program. Arch Dermatol. 2008; 144:515-21. (Pubitemid 351581109)
14. Bastiaannet E, Wobbes T, Hoekstra OS, van der Jagt EJ, Brouwers AH, Koelemij R, et al. Prospective comparison of [18F] fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. J Clin Oncol. 2009;27:4774-80.
15. Poos HP, Kruijff S, Bastiaannet E, van Ginkel RJ, Hoekstra HJ. Therapeutic groin dissection for melanoma: risk factors for short term morbidity. Eur J Surg Oncol. 2009;35:877-83.
16. Bastiaannet E, Beukema JC, Hoekstra HJ. Radiation therapy following lymph node dissection in melanoma patients: treatment, outcome and complications. Cancer Treat Rev. 2005;31:18-26. (Pubitemid 40246987)
17. Henderson MA, Burmeister B, Thompson JF, Di Iulio J, Fisher R, Hong A, et al. Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01). Ann Surg Oncol. 2009;27(18S):LBA9084.
18. Rossi CR, Mocellin S, Pasquali S, Pilati P, Nitti D. N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma. Ann Surg Oncol. 2008;15:310-5.
19. Xing Y, Badgwell BD, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, et al. Lymph node ratio predicts disease-specific survival in melanoma patients. Cancer. 2009;115:2505-13.
20. Berger AC, Fierro M, Kairys JC, Berd D, Sato T, Andrel J, et al. Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma. J Surg Oncol. 2012; 105:15-20.
21. Prens SP, van der Ploeg AP, van Akkooi AC, van Montfort CA, van Geel AN, de Wilt JH, et al. Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site. Ann Surg Oncol. 2011;18:3586-92.
22. de Vries M, Speijers MJ, Bastiaannet E, Plukker JT, Brouwers AH, van Ginkel RJ, et al. Long-term follow-up reveals that ulceration and sentinel lymph node status are the strongest predictors for survival in patients with primary cutaneous melanoma. Eur J Surg Oncol. 2011;37:681-7.